The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the efficacy of the combination of Thalidomide and Huang-Lian-Jie-Du-Tang on the patients with multiple myeloma in maintain therapy.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wuhan University
• Collaborator: Tongji Hospital
• Treatments: Oren gedoku to; Thalidomide

Criteria

Inclusion Criteria:

• patients can take HLJDT

Exclusion Criteria:

• patients can not take HLJDT